Monday, August 31, 2026

Aurora Cannabis Stock Takes A Hit: 13% Down At Opening

ViaNews Editorial Team

September 13, 2023

Aurora Cannabis Stock Takes A Hit: 13% Down At Opening

(VIANEWS) - Aurora Cannabis (NYSE: ACB) saw a steep 13.64% decrease to EUR0.83 at 10:02 EST Wednesday after five consecutive sessions of gains, yet broader market indices generally saw positive trends with the NYSE surging by 0.03% to EUR15,953.91 after three straight upticks.

About Aurora Cannabis

Aurora Cannabis Inc. is a Canadian company that specialises in producing and distributing cannabis-related products worldwide. Aurora operates across three segments - Canadian Cannabis, European Cannabis, and Plant Propagation. Aurora Cannabis produces medical and consumer cannabis products in Canada, distributes wholesale medical cannabis throughout Europe and international markets, propagate vegetables and ornamental plants across North America and provide propagated vegetables/ornamentals plants in North America. They also sell hemp-derived CBD products. Aurora Cannabis cultivates and sells various cannabis products, such as dried cannabis, oils, capsules, edibles, extracts and soft gels. Aurora offers recreational cannabis products and patient counseling services under various brands including Aurora Drift, San Rafael '71 Daily Special Whistler Being Greybeard. Based out of Leduc, Canada.

Technical Analysis

Aurora Cannabis (ACB) experienced an unprecedented spike in volume today, trading 2507,176 shares - which is 101.63% more than their average of 12,433,300 shares per day - suggesting there may be greater investor interest for their stock. Volatility analysis for this company found its intraday variation average for the past week, month, and quarter at 28.03%, 3.72% and 4.29%, respectively. The highest amplitude of average volatility over these time frames was 29.91% for week 2, month 1 and quarter 1 with 29.91% occurring over week 3. Aurora Cannabis stock has reached oversold status (=20), suggesting it may be undervalued and could experience a possible rebound soon. Given this information, investors may wish to monitor Aurora Cannabis stock for potential buying opportunities, particularly if its price continues to decrease. It should be remembered that stock prices can be affected by numerous factors and it is advised to conduct further research as well as consult a financial advisor prior to making any investment decisions.

Equity Analysis

Aurora Cannabis's trailing twelve months EPS value of EUR-10.54 indicates that they have not been profitable over the last twelve months. A negative EPS value could indicate significant expenses or losses which should raise concerns among potential investors. Aurora Cannabis may be investing heavily in growth initiatives that could pay dividends down the line, which should make potential investors cautious when using just EPS alone to evaluate their financial health. Prospective investors should also carefully consider other financial metrics, including revenue growth and cash flow as well as qualitative aspects like competitive position and regulatory environment before making investment decisions.

More news about Aurora Cannabis (ACB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com